Several studies have used extended statistical models that combine clinical factors like Gleason Grading Groups (GGG) or prostate-specific antigen (PSA) levels with multiparametric imaging, genomic or transcriptomic markers, or other biochemical markers to measure the risk of tumor progression [5–7]. The gene discussed is KLK3; the disease is neoplasm.